ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Trastuzumab

Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.

Drug pageTrastuzumab: every studyMany companies study it; this page follows only the 79 they lead. All 533 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 13, 201079 company-led studies, 4 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only470 open or runningphase 4since Dec 13, 2010May 2, 2000none ahead
Novartisits history only50 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizerits history only31 open or runningphase 3since Feb 14, 2022Oct 20, 2005Dec 31, 2027phase 3 · NCT05253651
Celltrionits history only20 open or runningphase 3since Jun 11, 2014Jun 11, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 2since Aug 31, 2007Aug 31, 2007none ahead
Jiangsu HengRui Medicineits history only22 open or runningphase 3since Aug 14, 2026Aug 17, 2025Oct 2027phase 2 · NCT07140393
Prestige Biopharmaits history only20 open or runningphase 3since Dec 29, 2016Dec 29, 2016none ahead
Sanofiits history only20 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Instituteits history only21 open or runningphase 2since Jun 27, 2007Jun 27, 2007none ahead
Tanvex BioPharma USAits history only20 open or runningphase 3since Jun 1, 2018Jun 1, 2018none ahead
Viatris10 open or runningphase 1since Oct 29, 2015Oct 29, 2015none ahead

Also a collaborator on its studies: Daiichi Sankyo, Medivation LLC, a wholly owned subsidiary of Pfizer, AbbVie, Zai Lab, Nippon Kayaku, MDS Pharma Services, Mylan and Dong-A Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2015First study: phase 1 study in HealthyFirst studyNCT02594761 · 132 enrolled
  2. Jun 9, 2016Named trastuzumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HD201

TargetBeta

ERBB2 →read by rule
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
pertuzumabruleHoffmann-La Rochephase 457
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

The one study Viatris leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02594761Healthy1CompletedFeb 2014132

How it is read

Names in the registry

  • “Trastuzumab”, 36 entries
  • “Herceptin”, 13 entries
  • “trastuzumab [Herceptin]”, 11 entries
  • “trastuzumab”, 9 entries
  • “HD201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.